MedTrace Logo

Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes

NCT00529230 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2018-10-25

No results posted yet for this study

Summary

Primary Objective:

1\. To determine the prevalence of secondary hypogonadism in male patients on chronic opioid therapy for cancer-related pain syndromes.

Secondary Objective:

1\. To determine the degree of sexual dysfunction, fatigue, and depression prevalent in male patients on chronic opioid therapy for cancer-related pain syndromes.

Conditions

Interventions

BEHAVIORAL

Questionnaire

A set of questionnaires regarding sexual function, physical and psychological symptoms.

OTHER

Blood draws to assess gonadal function

Testosterone, FSH, and LH levels at study onset.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Arun Rajagopal, MD · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-11
Primary Completion
2004-02-19
Completion
2004-02-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00529230 on ClinicalTrials.gov